SecBot SecBot
DEFA14A ·Filed Jun 1, 2026

PCRX

Pacira BioSciences, Inc.
NEUTRAL
Impact 5/10
Horizondays Processed5mo ago SEC0001628280-26-039589
Proxy solicitation materials
Actionable Insight • Neutral

With ISS and Glass Lewis both backing management's slate, the probability of Pacira's nominees winning the vote has increased. Monitor the June 9 meeting outcome; a management win removes near-term activist pressure for a sale and supports continued execution of the 5x30 strategy. A dissident win could accelerate strategic review or sale processes.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$22.25
T+0 close · Jun 1, 2026 · via day close
Latest settled
+16.40%
T+60 · $25.90
Vs SPY
+15.29%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 2 $22.25entry
  2. T+1 · 6mo ago +0.31%α +1.04% · $22.32
  3. T+5 · 5mo ago +4.31%α +7.28% · $23.21
  4. T+20 · 5mo ago +12.49%α +14.06% · $25.03
  5. T+60 · 3mo ago +16.40%α +15.29% · $25.90

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pacira BioSciences issued a press release highlighting that ISS has recommended stockholders vote FOR all three of Pacira's director nominees and AGAINST all three of DOMA Perpetual Capital Management's nominees at the June 9, 2026 annual meeting. ISS concluded the dissident has not presented a compelling case for change and that Pacira's board has been proactive in refreshment and strategy. This filing is management's solicitation material urging stockholders to support the company's slate ahead of a contested proxy vote.

Key Financial Metrics

Vote
director election
Meeting
2026-06-09
Seats Contested
3

Key Facts

  • ISS recommends voting FOR all three of Pacira's director nominees (Christopher Christie, Samit Hirawat, Thomas Wiggans) and AGAINST all three of DOMA Perpetual's nominees.
  • Annual Meeting scheduled for June 9, 2026.
  • ISS noted Pacira's performance 'measurably improved' following the launch of its 5x30 strategy and that the board has been proactive in refreshment and governance.
  • ISS stated the dissident has 'not presented a compelling case for change' and that its nominees lack public company board experience.
  • Glass Lewis previously also recommended supporting Pacira's nominees.
  • Goldman Sachs is acting as financial advisor and Perkins Coie as legal counsel to Pacira.

Financial Impact

No financial figures disclosed in this filing. The outcome of the proxy contest could influence strategic direction and capital allocation, but no deal values or financial metrics are provided.

Risk Factors

  • Dissident DOMA Perpetual may still win board seats if institutional voting diverges from proxy advisor recommendations.
  • Continued activist pressure could distract management or force a sale at an inopportune time.
  • The contested election creates near-term uncertainty around strategic direction.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001628280-26-039589
Document: 0001628280-26-039589-index-headers.html0001628280-26-039589
Document: 0001628280-26-039589-index.html0001628280-26-039589
Document: 0001628280-26-039589.txt0001628280-26-039589

Track record

29 reports on PCRX

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
  2. Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  3. Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
  5. Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
  6. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  7. Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  8. Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  9. Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
  10. Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026